Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Adma Biologics (ADMA) Accumulated Depreciation & Amortization (2016 - 2025)

Adma Biologics (ADMA) has disclosed Accumulated Depreciation & Amortization for 13 consecutive years, with $8.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Depreciation & Amortization rose 3.9% year-over-year to $8.0 million, compared with a TTM value of $8.0 million through Dec 2025, up 3.9%, and an annual FY2025 reading of $8.0 million, up 3.9% over the prior year.
  • Accumulated Depreciation & Amortization was $8.0 million for Q4 2025 at Adma Biologics, up from $2.0 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $8.0 million in Q4 2025 and bottomed at $1.1 million in Q1 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $3.3 million, with a median of $2.0 million recorded in 2023.
  • The sharpest move saw Accumulated Depreciation & Amortization soared 172.73% in 2022, then plummeted 58.7% in 2023.
  • Year by year, Accumulated Depreciation & Amortization stood at $4.8 million in 2021, then soared by 33.33% to $6.4 million in 2022, then increased by 18.75% to $7.6 million in 2023, then rose by 1.32% to $7.7 million in 2024, then increased by 3.9% to $8.0 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for ADMA at $8.0 million in Q4 2025, $2.0 million in Q3 2025, and $2.0 million in Q2 2025.